Head-to-head evidence
Rasagiline (Azilect) vs Safinamide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: MAO-B · full Parkinson's Disease pipeline
Rasagiline (Azilect)
Marketed by Teva Pharmaceutical Industries
NCT01479530 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled trial with 321 participants, with 158 assigned to placebo and 163 to rasagiline. The primary clinical endpoint—change in daily OFF time—favored rasagiline and was statistically significant (p=0.0228).
Safinamide · Xadago
Marketed by Zambon SpA and partners
NCT00605683 · Phase 3 · completed
The study was randomized and double-blind, included 679 participants, and compared two safinamide doses with placebo. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT07761936 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rasagiline (Azilect)'s landscape · Safinamide's landscape